Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF
BRAF(V600) mutations
efficacy
objective response rate
overall survival
progression-free survival
safety
vemurafenib
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
09
08
2023
revised:
14
09
2023
accepted:
21
09
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
BRAF inhibitors are approved in BRAF Patients with advanced tumours other than BRAF A total of 98 advanced patients with various solid or haematological cancers, 88 with BRAF Responses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
Sections du résumé
BACKGROUND
BACKGROUND
BRAF inhibitors are approved in BRAF
PATIENTS AND METHODS
METHODS
Patients with advanced tumours other than BRAF
RESULTS
RESULTS
A total of 98 advanced patients with various solid or haematological cancers, 88 with BRAF
CONCLUSION
CONCLUSIONS
Responses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
Identifiants
pubmed: 37922690
pii: S2059-7029(23)01279-6
doi: 10.1016/j.esmoop.2023.102038
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102038Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.